US appeals court affirms invalidity of Yasmin patent
This article was originally published in Scrip
Executive Summary
A US appeals court has upheld a lower court ruling that a key US patent on Bayer Schering Pharma's oral contraceptive Yasmin (drospirenone plus ethinylestradiol) is invalid.